Search results for " Drug"

showing 10 items of 3138 documents

Phenolic Compounds in Extra Virgin Olive Oil Stimulate Human Osteoblastic Cell Proliferation.

2016

In this study, we aimed to clarify the effects of phenolic compounds and extracts from different extra virgin olive oil (EVOO) varieties obtained from fruits of different ripening stages on osteoblast cells (MG-63) proliferation. Cell proliferation was increased by hydroxytyrosol, luteolin, apigenin, p-coumaric, caffeic, and ferulic acids by approximately 11-16%, as compared with controls that were treated with one vehicle alone, while (+)-pinoresinol, oleuropein, sinapic, vanillic acid and derivative (vanillin) did not affect cell proliferation. All phenolic extracts stimulated MG-63 cell growth, and they induced higher cell proliferation rates than individual compounds. The most effective…

0301 basic medicineTime Factorslcsh:MedicineBiochemistryMass SpectrometryTreeschemistry.chemical_compoundAnimal CellsPlant ProductsMedicine and Health SciencesCaffeic acidApigeninlcsh:ScienceLuteolinChromatography High Pressure LiquidConnective Tissue CellsCultured Tumor CellsPrincipal Component AnalysisMultidisciplinaryAgricultureCell DifferentiationRipeningPlantsPhenylethyl AlcoholLipidsOsteoblast DifferentiationChemistryBiochemistryCell ProcessesConnective TissuePhysical SciencesApigeninBiological CulturesCellular TypesAnatomyResearch ArticleOlive TreesCoumaric AcidsResearch and Analysis MethodsVegetable Oils03 medical and health sciencesCaffeic AcidsPhenolsOleuropeinCell Line TumorOleaVanillic acidHumansPhenolsOlive OilCell ProliferationAnalysis of Variance030109 nutrition & dieteticsOsteoblastsDose-Response Relationship Druglcsh:RChemical CompoundsOrganismsBiology and Life SciencesCell BiologyCell CulturesOsteosarcoma CellsAgronomyOlive treesBiological Tissue030104 developmental biologychemistryFruitHydroxytyrosollcsh:QOilsCrop ScienceDevelopmental Biology
researchProduct

An in vitro investigation on the cytotoxic and nuclear receptor transcriptional activity of the mycotoxins fumonisin B1 and beauvericin.

2016

Fumonisin B1 (FB1) and beauvericin (BEA) are secondary metabolites of filamentous fungi, which under appropriate temperature and humidity conditions may develop on various foods and feeds. To date few studies have been performed to evaluate the toxicological and endocrine disrupting effects of FB1 and BEA. The present study makes use of various in vitro bioassays including; oestrogen, androgen, progestagen and glucocorticoid reporter gene assays (RGAs) for the study of nuclear receptor transcriptional activity, the thiazolyl blue tetrazolium bromide (MTT) assay to monitor cytotoxicity and high content analysis (HCA) for the detection of pre-lethal toxicity in the RGA and Caco-2 human colon …

0301 basic medicineTranscription GeneticCell SurvivalBiologyAdenocarcinomaEndocrine DisruptorsToxicologyFumonisins03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyGlucocorticoid receptorReceptors GlucocorticoidGenes ReporterDepsipeptidesmedicineHumansCytotoxicityReceptorCell NucleusFumonisin B1Dose-Response Relationship Drug04 agricultural and veterinary sciencesGeneral Medicine040401 food scienceBeauvericin030104 developmental biologychemistryNuclear receptorBiochemistryReceptors AndrogenToxicityColonic NeoplasmsCaco-2 CellsReceptors ProgesteroneGlucocorticoidmedicine.drugToxicology letters
researchProduct

Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents

2016

Novel 1,4-benzodiazepines, endowed with a Michael acceptor moiety, were designed taking advantage of a computational prediction of their pharmacokinetic parameters. Among all the synthesized derivatives, we identified a new lead compound (i.e., 4a), bearing a vinyl ketone warhead and endowed with a promising antitrypanosomal activity against Trypanosoma brucei brucei (IC50 = 5.29 µM), coupled with a lack of cytotoxicity towards mammalian cells (TC50>100 µM).

0301 basic medicineTrypanosomaKetonePeptidomimeticPeptidomimeticStereochemistryTrypanosoma brucei bruceiClinical BiochemistryPharmaceutical ScienceTrypanosoma brucei01 natural sciencesBiochemistryCell LineBenzodiazepinesMiceStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundparasitic diseasesDrug DiscoveryAnimalsStructure–activity relationshipMoietyCytotoxicityMolecular BiologyMicrowave irradiationchemistry.chemical_classificationDose-Response Relationship DrugMolecular Structurebiology010405 organic chemistryMacrophagesOrganic Chemistrybiology.organism_classificationMichael acceptors Microwave irradiation Peptidomimetics Pharmacokinetic parameters TrypanosomaTrypanocidal Agents0104 chemical sciencesPharmacokinetic parameter030104 developmental biologychemistryMichael reactionMolecular MedicineMichael acceptorLead compoundBioorganic & Medicinal Chemistry Letters
researchProduct

Exosome-mediated drug resistance in cancer: the near future is here.

2016

Drug resistance exerts a crucial role in several cancer treatments. Understanding the resistance mechanisms against different therapeutic agents can be helpful to determine the prognosis, but remains a tricky task. In this context, tumor-derived exosomes (TDEs) may give crucial answers about these resistance mechanisms. Exosomes are biological nanovesicles with an average size around 30–100 nm of diameter (Figure 1) that originate from the endocytic pathway by the inward budding of multivesicular bodies (MVB), and they function as cell-free messengers, involved in the cell–cell communication [Kowal et al. 2014]. It has been demonstrated that both cells in physiological and pathological cond…

0301 basic medicineTumor microenvironmentAngiogenesisEndocytic cycleContext (language use)Drug resistanceBiologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282ExosomeMicrovesiclesCell biology03 medical and health sciencesEditorial030104 developmental biology0302 clinical medicineExosomes cancer drug resistanceOncologySettore BIO/13 - Biologia Applicata030220 oncology & carcinogenesismicroRNAImmunologyHuman medicine
researchProduct

An overview on anti-tubulin agents for the treatment of lymphoma patients

2020

Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the …

0301 basic medicineVinca alkaloidsLymphomaMitosisAntineoplastic AgentsApoptosismacromolecular substancesMicrotubulesAntibody drug conjugatesTaxanes03 medical and health sciences0302 clinical medicineTubulinMicrotubulemedicineAnimalsHumansMaytansinePharmacology (medical)MetaphaseMitosisAnaphasePharmacologybiologybusiness.industryCancerCombination chemotherapymedicine.diseaseTubulin ModulatorsLymphoma030104 developmental biologyTubulinEpothilones030220 oncology & carcinogenesisbiology.proteinCancer researchDolastatinsbusinessPharmacology & Therapeutics
researchProduct

Effect of Buthionine Sulfoximine on the Sensitivity to Doxorubicin of Parent and MDR Tumor Cell Lines

1994

We have studied the interaction of glutathione-depleting concentrations of buthionine sulfoximine (BSO) with the anti-proliferative activity of doxorubicin (DXR) in three tumor lines, the mouse B16 melanoma. Friend erythroleukemia and the human K562 leukemia, both as DXR-sensitive and-resistant (with typical multidrug resistance) variants. BSO significantly enhanced the DXR effects in the wild-type Friend and K562 leukemias, and especially in the drug-resistant subline of Friend leukemia. BSO did not modify DXR accumulation and retention in the latter clone. Moreover, neither BSO nor verapamil used alone completely reversed the resistance to DXR of this cell line; their combination was more…

0301 basic medicineVincristineFriend leukemia030106 microbiologyPharmacologyMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMethionine Sulfoximinehemic and lymphatic diseasesTumor Cells CulturedmedicineAnimalsHumansPharmacology (medical)DoxorubicinButhionine sulfoximineButhionine SulfoximinePharmacologyChemistryDrug SynergismGlutathionemedicine.diseaseGlutathioneDrug Resistance MultipleMultiple drug resistanceLeukemiaInfectious DiseasesOncologyDoxorubicinVincristine030220 oncology & carcinogenesismedicine.drugK562 cellsJournal of Chemotherapy
researchProduct

Repurposing old drugs to fight multidrug resistant cancers.

2020

Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approa…

0301 basic medicineVirtual screeningCancer ResearchDrug repurposingSettore BIO/11 - Biologia MolecolareAntineoplastic AgentsDrug resistanceBioinformatics03 medical and health sciencesClinical cancer trials; Drug repurposing; Multidrug resistant cancer; Pharmacophore modelling; Virtual screening0302 clinical medicineNeoplasmsDrug DiscoveryMedicineHumansPharmacology (medical)Computer SimulationRepurposingPharmacologyVirtual screeningDrug discoverybusiness.industryDrug RepositioningComputational BiologyDrug Resistance Multiple3. Good healthMultiple drug resistanceDrug repositioning030104 developmental biologyInfectious DiseasesOncologyDrug developmentDrug Resistance Neoplasm030220 oncology & carcinogenesisMultidrug resistant cancerPharmacophore modellingPharmacophorebusinessClinical cancer trialsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis

2018

Abstract Vitamin K antagonists (VKAs) have been used in 1% of the world’s population for prophylaxis or treatment of thromboembolic events for 64 years. Impairment of osteoblast function and osteoporosis has been described in patients receiving VKAs. Given the involvement of cells of the bone marrow microenvironment (BMM), such as mesenchymal stem cells (MSCs) and macrophages, as well as other factors such as the extracellular matrix for the maintenance of normal hematopoietic stem cells (HSCs), we investigated a possible effect of VKAs on hematopoiesis via the BMM. Using various transplantation and in vitro assays, we show here that VKAs alter parameters of bone physiology and reduce funct…

0301 basic medicineVitamin KImmunologyPopulationBone Marrow CellsPeriostinBiochemistryMice03 medical and health sciences0302 clinical medicineLeukocytesAnimalsMedicineeducationeducation.field_of_studyDose-Response Relationship Drugbusiness.industryMacrophagesMonocyteMesenchymal stem cellAnticoagulantsCell BiologyHematologyHematopoietic Stem CellsHematopoiesisTransplantationHaematopoiesis030104 developmental biologymedicine.anatomical_structureCellular MicroenvironmentMyelodysplastic Syndromes030220 oncology & carcinogenesisCancer researchWarfarinBone marrowStem cellbusinessCell Adhesion MoleculesBiomarkersBlood
researchProduct

Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems

2020

Cystic fibrosis (CF) patients develop a severe form of the disease when the cystic fibrosis transmembrane conductance regulator (CFTR) gene is affected by nonsense mutations. Nonsense mutations are responsible for the presence of a premature termination codon (PTC) in the mRNA, creating a lack of functional protein. In this context, translational readthrough-inducing drugs (TRIDs) represent a promising approach to correct the basic defect caused by PTCs. By using computational optimization and biological screening, we identified three new small molecules showing high readthrough activity. The activity of these compounds has been verified by evaluating CFTR expression and functionality after…

0301 basic medicineYellow fluorescent proteinCystic Fibrosisnonsense mutationCystic Fibrosis Transmembrane Conductance RegulatorCystic fibrosislcsh:Chemistry0302 clinical medicinelcsh:QH301-705.5SpectroscopyCells CulturedbiologyChemistryGeneral MedicineSmall moleculeCystic fibrosis transmembrane conductance regulatorComputer Science ApplicationsCell biologyCodon Nonsense030220 oncology & carcinogenesisNonsense mutationContext (language use)Settore BIO/11 - Biologia MolecolareCatalysisArticleInorganic Chemistry03 medical and health sciencesmedicineHumansRNA MessengerPhysical and Theoretical ChemistryMolecular BiologyGeneMessenger RNAOrganic ChemistryoxadiazolesSettore CHIM/06 - Chimica Organicapremature termination codonmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaSettore BIO/18 - Genetica030104 developmental biologyGene Expression Regulationlcsh:Biology (General)lcsh:QD1-999translational readthrough inducing drugsProtein BiosynthesisMutationbiology.proteingenetic disorderInternational Journal of Molecular Sciences
researchProduct

Statement of the Prolamin Working Group on the Determination of Gluten in Fermented Foods Containing Partially Hydrolyzed Gluten

2021

On August 12, 2020, the U.S. Food and Drug Administration (FDA) has finalized a rule related to gluten-free labeling for foods containing fermented, hydrolyzed ingredients. The FDA believes that there is no scientifically valid analytical method effective for determining gluten in fermented or hydrolyzed foods. In the absence of an analytical method, the FDA has decided to evaluate gluten-free claims on these foods based only on evidence that the food or ingredient used is gluten-free before fermentation or hydrolysis. For example, barley-based beers from which gluten is removed during brewing using special filtration, adsorption and/or enzymatic treatment are therefore excluded from bearin…

0301 basic medicineanalysifermented foodanalysisEndocrinology Diabetes and MetabolismIngredientProlaminFood scienceIngredient0302 clinical medicinehydrolysed beer[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood scienceFermentation in food processingComputingMilieux_MISCELLANEOUS2. Zero hungerchemistry.chemical_classificationNutrition and DieteticsbiologyChemistryHydrolysisdigestive oral and skin physiologyfood and beveragesQuímicaChemistryFermentation in food processingProlamin Working Groupgluten-free foodpartially hydrolyzed glutenlcsh:Nutrition. Foods and food supplyLife sciences; biologyOpinioncompetitive ELISAlcsh:TX341-641030209 endocrinology & metabolismdigestive systemFood and drug administration03 medical and health sciencesHydrolysisddc:570ProlaminLC-MS/MSFood and drug administrationNutrition030109 nutrition & dieteticsbusiness.industrynutritional and metabolic diseasesBrewingGlutendigestive system diseasesPlant BreedingglutenFermentationbiology.proteinBrewingFermentation[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionceliac diseaseFrontiers in Nutrition
researchProduct